학술논문
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Document Type
Article
Author
Orkin, Chloe ; Oka, Shinichi; Philibert, Patrick; Brinson, Cynthia; Bassa, Ayesha; Gusev, Denis; Degen, Olaf; García, Juan González; Morell, Enrique Bernal; Tan, Darrell H S; D'Amico, Ronald; Dorey, David; Griffith, Sandy; Thiagarajah, Shanker; St Clair, Marty; Van Solingen-Ristea, Rodica; Crauwels, Herta; Ford, Susan L; Patel, Parul; Chounta, Vasiliki; Vanveggel, Simon; Cutrell, Amy; Van Eygen, Veerle; Vandermeulen, Kati; Margolis, David A; Smith, Kimberly Y; Spreen, William R
Source
In The Lancet HIV April 2021 8(4):e185-e196
Subject
Language
ISSN
2352-3018